Literature DB >> 10544082

HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro.

A T Das1, A Land, I Braakman, B Klaver, B Berkhout.   

Abstract

HIV-1 LAI is a syncytium-inducing (SI) virus with a broad host cell range. We previously isolated a LAI variant that improved replication in the SupT1 T cell line due to mutations within the C1 and C4 constant regions of the Env protein. We now report that this variant exhibits a severely restricted host cell range, as replication in other T cell lines and primary cells was abolished. Several Env-mediated functions were analyzed to provide a mechanistic explanation for this selective adaptation. The change in host cell tropism was not caused by a switch to a SupT1-specific coreceptor. Biosynthesis of the variant Env glycoprotein was not improved in SupT1 cells, and in fact a small defect in intracellular Env processing was observed. SupT1 infection assays did not reveal an improved Env function either, and a dramatic loss of infectivity was measured with other cell types. The Env-mutated HIV-1 reached an approximately fivefold higher level of virus production in SupT1 cells at the peak of infection. Unlike the LAI virus, the variant did not trigger the formation of syncytia. Our combined results suggest that the HIV-1 variant allows the infected host cell to survive longer, thus producing more viral progeny. The intricate virus-cell interaction results in a balance between optimal virus replication and host cell survival, causing a cytopathic SI isolate to evolve toward a nonsyncytium-inducing (NSI) phenotype in cell culture. These findings may help explain the absence of SI variants in the initial phase of HIV-1 infection, and the results dispute the notion that HIV-1 evolution should always go from the NSI to SI phenotype. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544082     DOI: 10.1006/viro.1999.9898

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

Review 3.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

4.  Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein.

Authors:  Eelco van Anken; Rogier W Sanders; I Marije Liscaljet; Aafke Land; Ilja Bontjer; Sonja Tillemans; Alexey A Nabatov; William A Paxton; Ben Berkhout; Ineke Braakman
Journal:  Mol Biol Cell       Date:  2008-07-23       Impact factor: 4.138

5.  Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Authors:  Rachel Van Duyne; Lillian S Kuo; Phuong Pham; Ken Fujii; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

6.  Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription.

Authors:  Giuseppe Marzio; Monique Vink; Koen Verhoef; Anthony de Ronde; Ben Berkhout
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure?

Authors:  Jonathan Fior
Journal:  Viruses       Date:  2013-02-21       Impact factor: 5.048

8.  An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individuals.

Authors:  Jonathan Fior
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

9.  Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.

Authors:  Chris E Baldwin; Ben Berkhout
Journal:  Retrovirology       Date:  2006-11-29       Impact factor: 4.602

10.  SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice.

Authors:  Jonathan Fior
Journal:  Vaccines (Basel)       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.